Trial Profile
The BEACON Study (BrEAst Cancer Outcomes with NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician's Choice (TPC) in Patients with Locally Recurrent or Metastatic Breast Cancer Previously Treated with an Anthracycline, a Taxane, and Capecitabine
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Etirinotecan pegol (Primary) ; Antineoplastics
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms BEACON
- Sponsors Nektar Therapeutics
- 19 Sep 2018 Results presented in an ApoCell Media Release.
- 04 Apr 2018 Results of biomarker analysis evaluating biomarkers from circulating tumour cells as an alternative to tumor bopsies published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 27 Mar 2017 Results assessing Health-related quality of life (n=733), published in the European Journal of Cancer